Brief: Infinimmune Raises $75 Million Series A Financing To Advance Pipeline Of Human-Derived Antibodies For Atopic Dermatitis And Inflammatory Disease
11/08/2026 13:32
BRIEF-Infinimmune Raises $75 Million Series A Financing To Advance Pipeline Of Human-Derived Antibodies For Atopic Dermatitis And Inflammatory Disease Aug 11 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
INFINIMMUNE RAISES $75 MILLION SERIES A FINANCING TO ADVANCE PIPELINE OF HUMAN-DERIVED ANTIBODIES FOR ATOPIC DERMATITIS AND INFLAMMATORY DISEASE
INFINIMMUNE: $75 MILLION SERIES A FINANCING CO-LED BY REGENERON VENTURES AND PLAYGROUND GLOBAL
Source text: ID:nBw6SNcZda
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement